# HUINNO AIM

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/huinno-aim

- Industry: Medical Devices & Equipment
- Headquarters: Seoul, South Korea
- Website: www.huinnoaim.com
- Total disclosed funding: $3M
- Latest round: Seed (Aug 17, 2022)
- Investors on record: 4

## About

Based in South Korea, and founded in 2022, HUINNO AIM operates as a HealthTech (healthcare technology) company. In August 2022, HUINNO AIM raised KRW 4 billion in seed funding from Yuhan Corporation, HUINNO Co., Ltd., FuturePlay, and AON Investment. As of 2022, the company’s CEO is Young-Jun Gil.

HUINNO AIM offers (artificial intelligence) AI-based CDSS (clinical decision support system), which is a device that helps in the clinical diagnosis and predicts a wide range of diseases. The company's AI technology gathers and analyzes biosignals including oxygen saturation (SpO2), respiration (RR), and body temperature (BT) to assist hospitals and medical staff in making better clinical diagnosis judgments.

The company plans to use the funds raised in August 2022 to strengthen its research and development capabilities.

## Funding rounds

- Seed, Aug 17, 2022, $3M — FuturePlay, Yuhan Corporation, HUINNO Co., Ltd., AON Investment

## Investors

- FuturePlay (https://capitalatlas.ai/funds/futureplay) — Seed
- Yuhan Corporation — Seed
- HUINNO Co., Ltd. — Seed
- AON Investment (https://capitalatlas.ai/funds/aon-investment) — Seed